TY - JOUR
T1 - First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings
T2 - results from a prospective cohort of participants residing in congregate facilities in India
AU - Tsundue, Tenzin
AU - Namdon, Tenzin
AU - Tsewang, Tenzin
AU - Topgyal, Sonam
AU - Dolma, Tashi
AU - Lhadon, Dekyi
AU - Choetso, Tsering
AU - Woesal, Tenzin
AU - Yangkyi, Tenzin
AU - Gupta, Amita
AU - Peters, David
AU - Paster, Zorba
AU - Phunkyi, Dawa
AU - Sadutshang, Tsetan Dorji
AU - Chaisson, Richard E.
AU - Dorjee, Kunchok
N1 - Funding Information:
This work is being supported by individual philanthropist including The Chao Family, Ms Ann Down, the Johns Hopkins University Alliance for a Healthier World (80045453); US NIH/NIAID (K01AI148583); UN-STOP TB PARTNERSHIP TB REACH Wave 7 (STBP/TBREACH/GSA/W7-7692); The Pittsfield Anti-Tuberculosis Association and Friends of the Delek Hospital
Publisher Copyright:
© 2022 BMJ Publishing Group. All rights reserved.
PY - 2022/5/24
Y1 - 2022/5/24
N2 - Objectives This study aimed to determine the effectiveness of Covishield vaccine among residents of congregate residential facilities. Design A prospective cohort study in congregate residential facilities. Setting Dharamshala, Himachal Pradesh, India, from December 2020 to July 2021. Participants Residents of all ages in seven facilities - three monasteries, two old age homes and two learning centres - were enrolled. Exposures First and second doses of Covishield vaccine against SARS-CoV-2 infection. Main outcomes measures Primary outcome was development of COVID-19. Secondary outcome was unfavourable outcomes, defined as a composite of shortness of breath, hospitalisation or death. Vaccine effectiveness (%) was calculated as (1-HR)×100. Results There were 1114 residents (median age 31 years) participating in the study, 82% males. Twenty-eight per cent (n=308/1114) were unvaccinated, 50% (n=554/1114) had received one dose and 23% (n=252/1114) had received two doses of Covishield. The point prevalence of COVID-19 for the facilities ranged from 11% to 57%. Incidence rates (95% CI) of COVID-19 were 76 (63 to 90)/1000 person-months in the unvaccinated, 25 (18 to 35)/1000 person-months in recipients of one dose and 9 (4 to 19)/1000 person-months in recipients of two doses. The effectiveness of first and second doses of Covishield were 71% (adjusted HR (aHR) 0.29; 95% CI 0.18 to 0.46; p<0.001) and 80% (aHR 0.20; 95% CI 0.09 to 0.44; p<0.001), respectively, against SARS-CoV-2 infection and 86% (aHR 0.24; 95% CI 0.07 to 0.82; p=0.023) and 99% (aHR 0.01; 95% CI 0.002 to 0.10; p<0.001), respectively, against unfavourable outcome. The effectiveness was higher after 14 days of receiving the first and second doses, 93% and 98%, respectively. Risk of infection was higher in persons with chronic hepatitis B (aHR 1.78; p=0.034) and previous history of tuberculosis (aHR 1.62; p=0.047). Conclusion Covishield was effective in preventing SARS-CoV-2 infection and reducing disease severity in highly transmissible settings during the second wave of the pandemic driven by the Delta variant.
AB - Objectives This study aimed to determine the effectiveness of Covishield vaccine among residents of congregate residential facilities. Design A prospective cohort study in congregate residential facilities. Setting Dharamshala, Himachal Pradesh, India, from December 2020 to July 2021. Participants Residents of all ages in seven facilities - three monasteries, two old age homes and two learning centres - were enrolled. Exposures First and second doses of Covishield vaccine against SARS-CoV-2 infection. Main outcomes measures Primary outcome was development of COVID-19. Secondary outcome was unfavourable outcomes, defined as a composite of shortness of breath, hospitalisation or death. Vaccine effectiveness (%) was calculated as (1-HR)×100. Results There were 1114 residents (median age 31 years) participating in the study, 82% males. Twenty-eight per cent (n=308/1114) were unvaccinated, 50% (n=554/1114) had received one dose and 23% (n=252/1114) had received two doses of Covishield. The point prevalence of COVID-19 for the facilities ranged from 11% to 57%. Incidence rates (95% CI) of COVID-19 were 76 (63 to 90)/1000 person-months in the unvaccinated, 25 (18 to 35)/1000 person-months in recipients of one dose and 9 (4 to 19)/1000 person-months in recipients of two doses. The effectiveness of first and second doses of Covishield were 71% (adjusted HR (aHR) 0.29; 95% CI 0.18 to 0.46; p<0.001) and 80% (aHR 0.20; 95% CI 0.09 to 0.44; p<0.001), respectively, against SARS-CoV-2 infection and 86% (aHR 0.24; 95% CI 0.07 to 0.82; p=0.023) and 99% (aHR 0.01; 95% CI 0.002 to 0.10; p<0.001), respectively, against unfavourable outcome. The effectiveness was higher after 14 days of receiving the first and second doses, 93% and 98%, respectively. Risk of infection was higher in persons with chronic hepatitis B (aHR 1.78; p=0.034) and previous history of tuberculosis (aHR 1.62; p=0.047). Conclusion Covishield was effective in preventing SARS-CoV-2 infection and reducing disease severity in highly transmissible settings during the second wave of the pandemic driven by the Delta variant.
KW - COVID-19
KW - Epidemiology
KW - Public Health
UR - http://www.scopus.com/inward/record.url?scp=85130904326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130904326&partnerID=8YFLogxK
U2 - 10.1136/bmjgh-2021-008271
DO - 10.1136/bmjgh-2021-008271
M3 - Article
C2 - 35609920
AN - SCOPUS:85130904326
SN - 2059-7908
VL - 7
JO - BMJ Global Health
JF - BMJ Global Health
IS - 5
M1 - e008271
ER -